NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Hansa Biopharma AB (publ) (OTCGREY: HNSBF)

 
HNSBF Technical Analysis
5
As on 25th Dec 2024 HNSBF STOCK Price closed @ 2.83 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.69 & Strong Sell for SHORT-TERM with Stoploss of 5.21 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

HNSBFSTOCK Price

Open 2.93 Change Price %
High 2.93 1 Day -0.82 -22.47
Low 2.83 1 Week -0.82 -22.47
Close 2.83 1 Month -0.10 -3.41
Volume 150 1 Year -2.46 -46.50
52 Week High 5.29 | 52 Week Low 2.26
 
OTCGREY USA Most Active Stocks
IARED 24.62 %
CVMCA 22.54 -0.75%
JRVMF 0.01 0.00%
GXRFF 0.02 0.00%
GCEA 29.00 -21.20%
AHLD 82.75 -2.93%
MAXC 1.78 0.00%
KAKZF 110.12 4.72%
MNSLV 25.50 1.03%
FSEN 2.50 %
 
OTCGREY USA Top Gainers Stocks
GGLXF 0.10 900.00%
WSKEF 15.60 547.30%
GPACF 0.25 400.00%
GPACF 0.25 400.00%
CLYYF 0.65 170.83%
CUIRF 0.08 166.67%
MMCLF 0.63 103.23%
ASTTF 0.04 100.00%
KRLTF 0.07 75.00%
ARCXF 0.41 75.00%
 
OTCGREY USA Top Losers Stocks
PTHIF 0.07 -90.91%
PTHIF 0.07 -90.91%
SLMLF 0.02 -80.00%
SLMLF 0.02 -80.00%
DRVYF 0.01 -75.00%
BLBRF 0.05 -70.59%
GPGNF 0.50 -68.15%
TNSTF 0.01 -66.67%
NXFNF 5.34 -59.14%
ACPIF 0.03 -57.14%
 
 
HNSBF
Daily Charts
HNSBF
Intraday Charts
Whats New @
Bazaartrend
HNSBF
Free Analysis
 
HNSBF Important Levels Intraday
RESISTANCE3.02
RESISTANCE2.96
RESISTANCE2.92
RESISTANCE2.88
SUPPORT2.78
SUPPORT2.74
SUPPORT2.70
SUPPORT2.64
 
HNSBF Forecast April 2025
4th UP Forecast2.83
3rd UP Forecast2.83
2nd UP Forecast2.83
1st UP Forecast2.83
1st DOWN Forecast2.83
2nd DOWN Forecast2.83
3rd DOWN Forecast2.83
4th DOWN Forecast2.83
 
HNSBF Weekly Forecast
4th UP Forecast2.83
3rd UP Forecast2.83
2nd UP Forecast2.83
1st UP Forecast2.83
1st DOWN Forecast2.83
2nd DOWN Forecast2.83
3rd DOWN Forecast2.83
4th DOWN Forecast2.83
 
HNSBF Forecast2025
4th UP Forecast8.67
3rd UP Forecast6.8
2nd UP Forecast5.64
1st UP Forecast4.48
1st DOWN Forecast1.18
2nd DOWN Forecast0.02
3rd DOWN Forecast-1.14
4th DOWN Forecast-3.01
 
Hansa Biopharma AB (publ) ( OTCGREY USA Symbol : HNSBF )
Sector : N/A And Other Stocks in Same Sector
 
HNSBF Other Details
Segment EQ
Market Capital 653134336.00
Sector
Industry
Offical website >
 
HNSBF Address
HNSBF
 
HNSBF Latest News
 
Your Comments and Response on Hansa Biopharma AB (publ)
 
HNSBF Business Profile
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an IgG-degrading enzyme of Streptococcus pyogenes (IdeS), an antibody cleaving enzyme that is in Phase II for enabling kidney transplantations in sensitized patients, as well as for anti-GBM antibody disease and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), a cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden. Address: Scheelevägen 22, Lund, Sweden, 222 63
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service